β Agonist Delivery by High-Flow Nasal Cannula During COPD Exacerbation.
BACKGROUND: Whereas high-flow nasal cannula (HFNC) oxygen therapy is increasingly used in patients with exacerbation of COPD, the effectiveness of β2 agonist nebulization through HFNC has been poorly assessed. We hypothesized that salbutamol vibrating-mesh nebulization through HFNC improves pulmonar...
| Publicado en: | Respiratory Care Vol. 67; no. 1; pp. 9 - 16 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Mary Ann Liebert, Inc.
Jan2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=154455487&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 154455487 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00201324 4GG jtl: Respiratory Care issn: 00201324 maglogo: N pubinfo: dt: Jan2022 vid: 67 iid: 1 pid: 1365 pub: Mary Ann Liebert, Inc. place: New Rochelle, New York artinfo: ui: 154455487 154455487 154455487 10.4187/respcare.09242 154455487 ppf: 9 ppct: 7 formats: fmt: @attributes: type: P tig: atl: β Agonist Delivery by High-Flow Nasal Cannula During COPD Exacerbation. aug: au: Beuvon, Clément Coudroy, Rémi Bardin, Justine Marjanovic, Nicolas Rault, Christophe Bironneau, Vanessa Drouot, Xavier Robert, René Thille, Arnaud W. Frat, Jean-Pierre affil: INSERM CIC-1402, ALIVE Research Group, University of Poitiers, Poitiers, France sug: subj: Pulmonary Disease, Chronic Obstructive Therapy Disease Exacerbation Therapy Albuterol Administration and Dosage Surgical Mesh Nebulizers and Vaporizers Nasal Cannula Oxygen Therapy Equipment and Supplies Respiratory Function Tests Human Physiological Studies Prospective Studies Crossover Design Intensive Care Units Spirometry Forced Expiratory Volume Physiology Diagnostic Imaging Glasgow Coma Scale Scales Dyspnea Software Peak Expiratory Flow Rate Evaluation Tidal Volume Evaluation Quantitative Studies Descriptive Statistics Comparative Studies T-Tests Data Analysis Software Sex Factors Age Factors Confidence Intervals ab: BACKGROUND: Whereas high-flow nasal cannula (HFNC) oxygen therapy is increasingly used in patients with exacerbation of COPD, the effectiveness of β2 agonist nebulization through HFNC has been poorly assessed. We hypothesized that salbutamol vibrating-mesh nebulization through HFNC improves pulmonary function tests in subjects with COPD. METHODS: We conducted a physiological crossover study including subjects admitted to the ICU for severe exacerbation of COPD. After subject improvement allowing a 3-h washout period without bronchodilator, pulmonary function tests were performed while breathing through HFNC alone and after salbutamol vibrating-mesh nebulization through HFNC. The primary end point consisted in the changes in FEV1 before and after salbutamol nebulization. Secondary end points included the changes in FVC, peak expiratory flow (PEF), airway resistance, and clinical parameters. RESULTS: Among the 15 subjects included, mean (SD) FEV1 significantly increased after salbutamol nebulization from 931 mL (383) to 1,019 (432), mean difference +87 mL (95% CI 30-145) (P 5 .006). Similarly, FVC and PEF significantly increased, +174 mL (95% CI 66-282) (P 5 .004) and +0.3 L/min (95% CI 0-0.6) (P 5 .037), respectively. Airway resistances and breathing frequency did not significantly differ, whereas heart rate significantly increased after nebulization. CONCLUSIONS: In subjects with severe exacerbation of COPD, salbutamol vibrating-mesh nebulization through HFNC induced a significant bronchodilator effect with volume and flow improvement. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|